4.6 Review

When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease A Randomized Clinical Trial

Orly Vardeny et al.

Summary: In patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations compared with standard-dose quadrivalent inactivated influenza vaccine, but influenza vaccination remains strongly recommended in this population.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Medicine, General & Internal

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Editorial Material Medicine, General & Internal

Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

Jacqueline Corrigan-Curay et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Editorial Material Medicine, General & Internal

Real-World Evidence - What Is It and What Can It Tell Us?

Rachel E. Sherman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Editorial Material Medicine, General & Internal

The Imperative of Overcoming Barriers to the Conduct of Large, Simple Trials

Zubin J. Eapen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

Article Health Care Sciences & Services

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

Kevin E. Thorpe et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)

Article Medicine, General & Internal

Statistics Notes - Blinding in clinical trials and other studies

SJ Day et al.

BRITISH MEDICAL JOURNAL (2000)